The present invention relates to dihydropyridine mineralocorticoid receptor modulating compounds having the structure: and their use in treating cardiovascular events.
本发明涉及具有以下结构的二氢吡啶矿物质皮质激素受体调节化合物及其在治疗心血管事件中的应用。
Iminium ion mediated cyclizations of 4-aryl-1,4-dihydropyridines. Bridging with olefins
作者:George D. Hartman、Wasyl Halczenko、Brian T. Phillips
DOI:10.1021/jo00214a005
日期:1985.7
1,4-Dihydropyridine antagonist activities at the calcium channel: a quantitative structure-activity relationship approach
作者:Robert A. Coburn、Mark Wierzba、Mark J. Suto、Alan J. Solo、A. M. Triggle、David J. Triggle
DOI:10.1021/jm00119a009
日期:1988.11
The effect of 46 1,4-dihydropyridine-type calcium channel antagonists on the tonic contractile response of longitudinal muscle strips of guinea pig ileum was determined. 2,6-Dimethyl-3,5-dicarbomethoxy-4-phenyl-1,4-dihydropyridine (13) and 13 ortho-, 15 meta-, and seven para-monosubstituted and 10 polysubstituted aromatic derivatives of 13 were studied. The pharmacological activities of the monosubstituted derivatives were best correlated by eq 10, log 1/C = 0.68 pi + 2.50 sigma m -0.47Lmeta -3.40B1para + 11.31, which had a correlation coefficient of 0.89. The full data set was best correlated by eq 11, log 1/C = 0.62 pi + 1.96 sigma m -0.44Lmeta -3.26B1para -1.51Lmeta' + 14.23, which had a correlation coefficient of 0.90. Equations of similar form but involving an ortho steric term were found to correlate the radioligand binding data for this class of compounds.
HARTMAN, G. D.;HALCZENKO, W.;PHILLIPS, B. T., J. ORG. CHEM., 1985, 50, N 14, 2427-2431